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Deconstructing Psychosis With Human Brain Imaging
Raquel E. Gur1,2, Matcheri S. Keshavan3, and Stephen
M. Lawrie4
2DepartmentofPsychiatry,UniversityofPennsylvania,Philadelphia,
Pennsylvania, USA; 3Department of Psychiatry and Behavioral
Neurosciences, Wayne State University, Detroit, Michigan, USA;
4Division of Psychiatry, University of Edinburgh, Scotland, UK
This review synthesizes our current knowledge on the neu-
robiology of psychosis from an array of in vivo brain-
imaging studies. The evidence base consists of hundreds
of studies of patients with schizophrenia and fewer on bi-
polar disorder but rarely providing direct comparisons
between the disorders or integration across methods. Rep-
licated findings in schizophrenia include reduced whole-
brain and hippocampal volume as potential vulnerability
markers, with further progression at onset; reduced N-
acetyl aspartate concentrations in hippocampus and
prefrontal cortex; striatal dopamine D2 receptors upregu-
lation; and alteration in the relation between frontal and
temporal activation. These findings are not attributable
to medication effects but are of unclear specificity and
may apply across the psychosis spectrum. There are con-
sistently replicated associations of psychotic symptoms
and cognitive impairment in both structural and functional
imaging in schizophrenia but not, as yet, in bipolar dis-
order. Therefore, it would be premature to dispense with
current diagnostic categories because direct comparisons
among them are rare, insufficient studies have examined
longitudinal changes, and long-term imaging outcome stud-
ies in first-episode psychosis have not yet been done. To ad-
dress these issues and make neuroimaging ‘‘clinically
relevant,’’ investigators will need to standardize their
approaches to data acquisition and analysis, and construct
the necessary range of ‘‘human brain maps,’’ to implement
studies that are sufficiently powered to provide reliable
data pertinent to deconstructing psychosis.
Key words: neuroimaging/schizophrenia/psychosis/brain
structure/brain function
Introduction
Advances in neuroimaging technologies have created
both opportunities and challenges in the study of psycho-
sis. Eager to obtain a ‘‘window to the mind,’’ neuroimag-
ing has been embraced by investigators applying diverse
methods to examine brain structure and function in psy-
chiatric disorders. With progress in quantitative compu-
tational anatomy methodologies, we are at the threshold
of an exciting era in psychiatric research that can capital-
ize on the ability to study the living brain with refined
approaches both for hypothesis testing and for explora-
tion. In vivo measurement is afforded by magnetic reso-
nance imaging (MRI) examining neuroanatomy through
structural MRI (sMRI), connectivity through diffusion
tensor imaging (DTI), and neurochemistry through mag-
netic resonance spectroscopy (MRS). Magnetic reso-
nance also enables examination of brain physiology
using functional MRI (fMRI) methods. Other functional
neuroimaging methods include positron emission to-
mography (PET), which enables measurement of local
cerebral glucose metabolism, blood flow, and receptor
function. Single-photon computed emission tomography
(SPECT) can also be used to measure cerebral perfusion
and receptor function.
The diversity and complementarity of neuroimaging
methods can place them in a crucial position for integra-
tive translational research. Neuroimaging can intersect
basic and clinical efforts in elucidating the underlying
processes of complex psychotic disorders. By supplying
data obtained on patients, neuroimaging has a firm
hold on the clinical phenotype, and by informing on brain
systems, it can link tomolecular substrates. Furthermore,
combining neuroimaging with genetic strategies can yield
a powerful methodology with unprecedented potential
for novel treatments (figure 1). The challenge we face
is making this happen by mobilizing the increasing array
of procedures and measures relevant to clinically impor-
tant questions such as diagnosis, course of illness, and
outcome.
After 3 decades of neuroimaging research, is the tech-
nology informative to efforts to deconstruct psychosis?
Based on brain-imaging studies can we examine a patient
with first-episode psychosis and determine with some
confidence whether schizophrenia or bipolar disorder
are on the horizon? Might we even be able to use imaging
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as an early diagnostic aid in those at genetic or symptom-
atic high risk?
The research agenda in neuroimaging and psychosis
has not been geared from the outset to be clinically rel-
evant in differential diagnosis. Rather, most studies in
psychosis have focused on 1 disorder with the explicit pri-
mary goal of understanding its specific pathophysiology.
An implicit secondary goal has been to improve diagnosis
and clinical management. When imaging, commonly
structural, has been applied clinically as part of the
workup of a psychotic patient, the purpose has been to
rule out a space occupying lesion or developmental mal-
formation that may potentially cause the psychosis. Al-
though incidental findings have been reported in MRI
studies of even healthy people1 and patients who present
with psychosis,2 such findings are infrequent and com-
monly asymptomatic. This is not to say that obtaining
a scan is of no value where an organic psychosis is sus-
pected; a recent analysis of 253 adult psychiatric patients
who underwent a clinical MRI, 38 (15%) had some form
of treatment modification as a result of the neuroimaging
findings, and in 6 patients a medical condition was iden-
tified as a result of the MRI.3 However, in the absence of
quantitative analysis, routine brain imaging cannot aid in
the differential diagnosis of psychosis without consider-
ing the clinical presentation.4 Thus far, studies using im-
aging techniques to determine prognosis or treatment
response have not generated sufficiently replicated find-
ings. There are, however, encouraging results from sev-
eral studies evaluating these technologies as possible
predictors of diagnosis.
Most neuroimaging studies have been conducted in
schizophrenia. A PubMed search in October 2006 shows
490 citations for ‘‘schizophrenia and neuroimaging’’ and
only 134 for ‘‘bipolar and neuroimaging.’’ Only 31 stud-
ies are cited for the conjunctive ‘‘schizophrenia and bipo-
lar and neuroimaging’’ query. Few prospective studies
contain the information that would permit comparison
between patients with schizophrenia and those with bipo-
lar illness. Inconsistent findings within disorders have of-
ten led to controversy and have been attributed to disease
heterogeneity. Over the past decade, advances in quanti-
tative techniques have established some firm findings
about schizophrenia and related disorders. As impor-
tantly, these techniques have also highlighted areas where
further study is required and where methodological prac-
tices need to be improved.
This article will briefly highlight the knowledge we
have gained about psychosis using brain-imaging meth-
ods by emphasizing the results from consistently repli-
cated studies, systematic reviews, and meta-analyses of
the relevant literature. We shall consider structural imag-
ing (sMRI, DTI), neurochemical imaging (MRS, re-
ceptor studies), and functional imaging techniques in
patients with schizophrenia and the affective psychoses,
including studies of at-risk populations. The latter enable
integration of genetic and neuroimaging paradigms in
our efforts to elucidate neurobiological mechanisms
that underlie these disorders that may guide treatments.
Structural Magnetic Resonance Imaging and Diffusion
Tensor Imaging
sMRI Studies of Patients
An extensive literature, presented in reviews4–6 and meta-
analyses,7–11 documents consistent morphometric differ-
ences between patients with schizophrenia and healthy
people. There is whole-brain volume reduction of about
3% in patients, particularly in gray matter,7,8 and a con-
comitant increase in cerebrospinal fluid (CSF). Volume
reductions have been most notable in frontotemporal
regions. Medial temporal lobe (MTL) structures and,
particularly, the hippocampus and amygdala are reduced
by a greater amount than the whole brain.6,10 This is also
probably true of the prefrontal cortex (PFC) and other
parts of the temporal lobe, particularly the superior tem-
poral gyrus (STG).5,8 There is evidence that the thalamus
is likewise reduced in volume to a greater extent than the
whole brain.11 The size of the corpus callosum, a white
matter fiber bundle, is reduced to a roughly similar extent
as the whole brain.9
The region of interest (ROI) analytic approach initially
applied has been replaced by automated methods for re-
gional parcellation and voxel-based morphometry that
can efficiently yield information on the entire brain, per-
mitting validation of reported findings and new discovery
of other affected regions. Based onmorphological param-
eters, it is possible to apply high-dimensional nonlinear
pattern classification techniques to quantify the degree
of separation of patients with schizophrenia and healthy
controls. Such procedures enable testing the potential of
sMRI as an aid to diagnosis. In a recent study of patients
with schizophrenia andhealthy controls, suchaprocedure
Fig. 1. A Schematic Representation of the Central Role of
Neuroimaging Intersecting Between Basic Science and Clinical
Applications.
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demonstrated average classification accuracy of 82% for
women and 85% for men.12 While such automated meth-
ods are promising, further investigation is needed and we
cannot yet rely solely upon such approaches.
Whole-brain size reductions observed in schizophrenia
have been demonstrated to have ‘‘concurrent validity’’ by
quantitative review of postmortem studies.13 A review of
computational voxel-based morphometry studies high-
lighted that they consistently find gray matter density
reductions in MTLs and the STG.14 Furthermore, there
are replicated associations between STG volumes and
positive symptoms and between MTL reductions and
memory impairment.6,15,16 Figure 2 illustrates application
of deformation-based morphometry to compare a sample
of patients with schizophrenia to healthy controls.12
These abnormalities are unlikely to be confounded by
factors such as antipsychotic medication or substance
abuse. Most MRI studies that examined the specific
ROIs, highlighted above, also evaluated possible rela-
tionships with antipsychotic medication status or doses
and very rarely find any—with the exception of some
parts of the basal ganglia. In particular, increases of
up to 20% in the volume of the globus pallidus are reg-
ularly related to first-generation (typical) antipsychotic
medication dose.8 A review examining the effect of typ-
ical antipsychotics on brain structure revealed basal gan-
glia volume increases and cortical gray matter decreases,
detectable even after a 12-week treatment period.17
However, most studies have involved indirect and
nonrandomized comparisons in analyses that seemingly
seek to establish that the second-generation (atypical)
antipsychotics have beneficial effects on neuroanatomy.
There are no consistently replicated accounts of par-
ticular drugs having beneficial effects in specific brain
regions. Because patients with psychosis may have
comorbid substance abuse, the possible effects of such
substances should also be considered. The effects of alco-
hol abuse on the brain are usually generalized, or show
a PFC rather than temporal lobe bias, and the abnormal-
ities in schizophrenia noted above are present in patients
with no history of alcohol abuse. It is unclear if cannabis
has any effects on brain structure, and other substances
are used too infrequently to be likely confounders.
More pertinent limitations of this literature are high-
lighted in a recent review of sMRI in first-episode schizo-
phrenia studies that confirms only a reduction in the
volumes of the whole brain and of the hippocampus.18
This raises the clear need for further studies of recent on-
set patients to determine if other abnormalities are evi-
dent at that time or if they are progressive19; although
it will clearly be very difficult, if not impossible, to dis-
tinguish the effects of illness duration from the effects
of ongoing antipsychotic treatment.
Notably, similar findings, at least concerning the whole
brain andhippocampus, are evident in dementia. The cog-
nitive deficits in schizophrenia and its early characteriza-
tion as dementia praecox buttress that similar brain
systemsmaybe affected, with an underlying different neu-
ropathology and decades apart. Of more direct clinical
concern, as the structural neuroimaging literature in bipo-
lar disorder and depression accrues, it seems that the neu-
roanatomy of affective disorder is qualitatively similar to
Fig. 2. Effect sizes of control/patient group difference, calculated separately for neuroleptic-naive (top) and treated patients
with Schizophrenia (bottom). The spatial patterns are similar, except that treated patients display generally stronger effect sizes. Blue
means that the respective structures were relatively larger in patients than in healthy controls. Thus, treated patients showed a pronounced
increase in basal ganglia volumes. (from Davatzikos et al12)
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that in schizophrenia but merely less marked in quantita-
tive terms. At present, the only disease-specific finding is
that patients with bipolar disorder may not have whole-
brain volume reduction that is evident in schizophre-
nia,20–23 may not show volume reductions in amygdala
and may even show volume increases in amygdala at par-
ticular stages of the illness.23 It is now clear that the hip-
pocampus is reduced in volume even in depression.24,25
These hippocampal reductionsmaybe related to the num-
ber of depressive episodes and may even be more marked
in patients with severe depression than in the general pop-
ulation of patients with schizophrenia. Finally, there are
consistent reports and meta-analyses of an increased fre-
quency of signal hyperintensities in affective disorder22–27
that may be specific but of uncertain pathologenesis.
There have been too few direct comparisons of patients
with schizophrenia and bipolar disorder, let alone other
psychoses, to evaluate neuroanatomical differences
among the disorders. These studies have relatively small
samples and few have addressed changes over time—the
basis on which the disorders were originally separated.
A useful strategy that can address the issue of diagnostic
specificity isthestudyofpatientswithfirst-episodepsycho-
sis who are followed longitudinally. Once the diagnosis is
established, intake sMRI measures are examined for pos-
sible differences among groups.28–32 The available reports
are inconsistent. For example, left prefrontal gray matter
volume reductionwasnoted in first-episode schizophrenia
and not in affective psychosis.28 However, in male adoles-
cents, increased CSF and reduced gray matter volumes in
the frontal lobes did not distinguish those who developed
schizophrenia from those who did not.31 Such studies are
important because they enable testing the hypothesis that
there is more progression of abnormalities in those with
first-episodepsychosiswhogoontodevelopschizophrenia
as compared with affective disorder, but this key question
would bemuchmore practicably and quickly addressed in
multicenter than single-center studies.
There is a relative lack of studies in the affective disor-
ders examining the associations of sMRI findings to clin-
ical and neurobehavioral features. In schizophrenia,
there are demonstrated associations betweenmemory dif-
ficulties and positive psychotic symptoms and the size of
the hippocampus, the STG, and the temporal lobe in gen-
eral and between executive function, negative symptoms,
and PFCmeasures,6,15,16 but these relationships have not
been documented in bipolar disorder.
Diffusion Tensor Imaging
DTI examines white matter integrity and is a more recent
addition to structural measures (figure 3). As might be
expected with such a rapidly developing technology,
there are some replicated findings in the schizophrenia
literature, but it has been particularly hampered by the
wide array of different approaches both to acquire the
data and to analyze it.33 With the development of trac-
tography techniques, a common approach by the imaging
community could facilitate progress. Although gray mat-
ter volume deficits are more marked than white matter
abnormalities in schizophrenia, reduced anisotropy (a
measure of directionality of flow of water molecules in
axons, thereby an index of white matter integrity) is ob-
served with DTI in many brain regions. This finding sug-
gests that white matter structure may be disorganized in
schizophrenia rather than reduced in size.33 One major
appeal of DTI is that it can directly test the prevailing
view of schizophrenia (and psychosis in general) as a dis-
connection disorder.
Studies of Relatives and Others ‘‘at Risk’’
sMRI studies of the MTL have been the focus of most
attention in people at risk. Early ROI studies tended
to examine the amygdala and hippocampus together
and consistently found reductions in relatives compared
with controls, but most relatives did not have volume
reductions to pathological levels.15,34 The balance of
the evidence was for hippocampal differences in particu-
lar, although there were some notable and quite large
negative studies. A comprehensive review concluded that
reducedhippocampiwere likelytobeavulnerabilitymarker
for schizophrenia.15 This view has recently been supported
by a systematic review and meta-analysis of studies of
Fig. 3. Illustration of DTI measures showing fractional anisotropy
(a, b) and with delineation of specific ROIs corresponding white
matter tracts can be visualized showing front-back (c) and left-right
callosal connectivity (d) (courtesy of R. Verma, University of
Pennsylvania).
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relativesthatfindshippocampalreductionsinrelatives,with
an effect size of about 0.3, and additional differences be-
tween relatives and patients.35
Despite the small number of studies, there are already
replicated computational voxel-based morphometry stud-
ies in the relatives of patients with schizophrenia vs bipolar
disorder. Both Job et al36 and Diwadkar et al37 found re-
duced gray matter in PFC in relatives at high risk for
schizophrenia. Similarly, both McIntosh et al38 and
McDonald et al39 have reported reductions in gray matter
density in prefrontal regions and thalamus in schizophre-
nia as distinct from no reductions in gray matter in these
regions in bipolar disorder. Reductions in the thalamus
have been reported as a measure of genetic liability to psy-
chosis in general.39,40
The implication of such findings is that there are dis-
sociable state and trait-imaging markers of psychosis.
Therefore, vulnerability markers may predict schizophre-
nia before clinical presentation, expecting further volume
reduction near the onset of psychosis. The 2 main studies
to have addressed these issues to date are the Edinburgh
High-Risk Study (EHRS) and the study conducted in
the Personal Assessment and Crisis Evaluation clinic in
Melbourne, Australia. These pioneering studies have ex-
amined large populations of people at risk, for genetic or
clinical reasons, over almost 10 years. A total of 5 articles
have been published by these 2 research groups concern-
ing the possible predictive utility of a reduced hippocam-
pal volume, and even different reports from the same
study are conflicting. Thus, it seems that any predictive
effect is inconsistent and atmost weak.41–45More encour-
agingly, both groups have also evaluated changes in brain
structure over time and reported complementary results.
Pantelis et al42 demonstrated reductions in gray matter in
the left parahippocampal and fusiform gyri, as well as
other regions in frontal and left cerebellar cortex, over
approximately a year in 11 people as they developed a di-
agnosis of psychosis, usually schizophrenia. Job et al43
revealed reductions in gray matter density in left (para)
hippocampal uncus, fusiform gyrus, and right cerebellar
cortex in 8 individuals at high risk, for familial reasons,
who developed schizophrenia on average 2.5 years after
the first of 2 scans, obtained approximately 18 months
apart. This replication suggests reductions in temporal
lobe structure around the time of transition to diagnosis
of psychosis and, to some extent, predating the conver-
sion. The EHRS in particular makes it clear that such
changes may occur years prior to diagnosis and cannot
be attributable to medication as none of the participants
were medicated until after their second scan and estab-
lishing their diagnosis.
The Edinburgh group has gone a step further and eval-
uated the diagnostic properties of these reductions in gray
matter density as a possible ‘‘early diagnostic test,’’ by
comparing the 8 subjects who had 2 scans and developed
schizophrenia with either 10 patients, with similar psy-
chotic symptoms at the time of scanning, who did not
go on to have schizophrenia, and 57 high-risk subjects
who had 2 scans regardless of whether or not they had
symptoms. In both cases, temporal lobe volume reduc-
tions show very promising diagnostic properties, with
positive predictive values (PPVs) of around 70% for these
regional reductions individually, and about 80% in com-
bination.46 These PPVs can be contrasted with much
lower values for psychotic symptoms and behavioral
measures. In the high-risk study, approximately 12.5%
of those ‘‘at risk’’ developed schizophrenia as did
(only) 25% of those with psychotic symptoms as well
and about 30% of those scoring poorly on the Rey Au-
ditory Verbal Learning Test and approximately 50% of
those scoring above the cutoff on schizotypy measures.44
Structural imaging clearly adds clinical value here, but
there are important questions about the practicality of
using such an approach in clinical practice and early di-
agnosis would only be justified if an intervention was
available for such patients.
Amajor limitation is the very small sample sizes in these
studies. Replication with larger samples is needed and can
best be achieved in multicenter collaborations. The stan-
dardization of imaging techniques and approaches to
analysis is essential for deriving a ‘human brain map’
with detailed information about relevant changes in brain
structure during the normal range of neurodevelopment.
Such extensive information might be required before
significant progress can be made in applying structural
imaging techniques to clinical issues in psychosis.
Neurochemical Imaging
Magnetic Resonance Spectroscopy
MRS provides a noninvasive tool to investigate metabo-
lites in the living human brain. Being safe, this technique
allows investigation of the effects of the illness course
as well as the medications on these metabolites. Much
MRS work has focused on investigating phosphorus
(31P-MRS) and proton-containing metabolites (1H-
MRS).47,48
Proton MRS metabolites include N-acetyl aspar-
tate (NAA), creatine, choline, myoinositol, glutamine,
glutamate, glutathione, and Gamma-aminobutyric acid
(GABA). NAA is mainly synthesized in neurons and is
therefore regarded as a putative marker for neuronal loss
or dysfunction.49,50 However, NAA levels may also reflect
the integrityofglial cells.51NAAisalso important formem-
brane phospholipid and mitochondrial metabolism.52,53
A reduction in NAA peaks is found in most studies
of patients with chronic schizophrenia. Such deficits en-
compass several brain regions, notably hippocampus
and frontal cortex. A recent systematic review and meta-
analysis of 64 published studies involving 1209 schizo-
phrenia patients and 1256 controls suggested consistent
925
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evidence of NAA reductions in the frontal lobes and the
hippocampus.54 NAA reductions appear to be associated
with cortical atrophy, cognitive impairment, and negative
symptoms.48 Furthermore, NAA reductions have been
correlated with increased illness duration55 supporting
the possibility of a progressive impairment of neuronal
integrity as the illness unfolds.
NAA reductions are established and clinically used in
studies of several neurological disorders including stroke
and multiple sclerosis. Among psychiatric disorders,
euthymic bipolar patients have decreases in NAA in fron-
tal lobe structures and hippocampus, reported in a review
of 22 studies involving 328 adult bipolar and 349 control
subjects.56 On the other hand, a systematic review and
meta-analysis by the same authors of Major Depressive
Disorder (MDD) indicated increased choline-containing
metabolites in the basal ganglia but no alteration of
NAA.57 The diagnostic specificity of NAA reduction
remains to be further clarified.
NAA reductions are present in first-degree relatives,
who are at Genetic High Risk (GHR) for Schizophrenia,
though the results are more variable than in patients.
Nonpsychotic relatives of schizophrenia patients showed
NAA/choline ratio reductions in the anterior cingu-
late.34,58 By contrast, Tibbo et al59 observed elevated
glutamatergic metabolites but no other metabolite alter-
ations in high-risk offsprings of schizophrenia patients in
a 3T MRS study. Jessen et al60 used proton MRS to
examine neurochemical characteristics of the brain in
people deemed clinically at high risk (CHR) for schizo-
phrenia (the prodromal state, defined by the presence
of subthreshold psychotic-like symptoms). They ob-
served that reduced NAA/choline ratios in the anterior
cingulate predicted psychosis during longitudinal fol-
low-up. Wood et al61 reported increased NAA/creatine
ratios in the dorslolateral prefrontal cortex in CHR sub-
jects; this findings did not predict those who ‘‘converted’’
to schizophrenia during follow-up. Collectively, these
observations suggest that alterations of NAA in prefron-
tal structures may represent a vulnerability indicator for
schizophrenia in GHR subjects and even less consistently
in CHR subjects. More data are needed to replicate these
observations if they have to be of any value as clinically
useful predictive markers for schizophrenia.
31P-MRS investigations in drug-naive first-episode
psychosis patients suggest increased membrane break-
down at the onset of psychosis,62–65 and in most studies,
there appears to be reduced membrane generation in
early and chronic schizophrenia. Cell membrane changes
occur prominently during cell generation, and synapto-
genesis, but also during cell degenerative processes such
as apoptotic elimination of dendrites and axons (pruning)
and cell death. Cell membrane alterations of patients with
schizophrenia are also well documented in peripheral and
postmortem brain tissue at different stages of the disorder
(forreviewseeBergeretal66).Suchfindingsmayreflectare-
duction in neurons, glia, or synapses in schizophrenia.
Studies of adolescent offspring at increased genetic risk
for schizophrenia show membrane alterations similar to
thoseobservedinpatientswithearlyschizophrenia67; these
changes are more pronounced in the at-risk adolescents
who have already begun to manifest psychopathology.68
Interestingly, patients with manic psychosis appear to
have an increase in membrane precursors,69 that may
reflect a compensatory increase in cell generation or syn-
aptogenesis during manic exacerbation of psychotic dis-
orders. This suggests that there might be somemeasure of
diagnostic specificity for 31P-MRS changes, but the num-
ber of studies in bipolar patients and other psychiatric
disorders is too small to have confident application of
these findings as clinical markers for diagnosis.
Neuroreceptor Studies
PET and SPECT provide an important avenue to exam-
ine in vivo neurochemistry. The investigation of receptor
function with PET followed progress with in vitro bind-
ing measurements and autoradiography. Earlier ligand
studies in schizophrenia have examined primarily dopa-
mine (DA) receptor properties and particularly D2. The
application of D2 receptor PET studies to neuroleptic-na-
ive patients yielded initially somewhat inconsistent
results; data from Johns Hopkins investigators showed
increased occupancy with11 C-N-methylspiperone,70 but
Karolinska investigators using11 C-Raclopride did not.71
These discrepancies in the literature might be related to
several factors, such as differences in patient population,
ligands used, and modeling methods.72 The emphasis in
studying neuroleptic-naive patients in a limited number
of settings that can apply the technology resulted in rela-
tively small samples with commonly less than 20 patients
per study. However, an early systematic review of 17 post-
mortem and PET studies found a large effect size of almost
1.5,73 accompaniedby increases inbothD2 receptordensity
and affinity. Several comprehensive reviews have come to
the same conclusion.74,75
A consistent literature has emerged indicating increased
presynaptic dopaminergic turnover in schizophrenia. Such
studies measured striatal fluorodopa uptake as an index
of increased dopa decarboxylase activity and greater pre-
synaptic DA turnover in the striatum. Increased activity of
DA neurons in the striatum appears to be associated with
clinical status and is more evident during acute exacerba-
tions and presence of positive symptoms.75 Notably, such
effects are consistent with studies of neuropharmacologi-
cal stimulants, such as amphetamine, and cannot be attrib-
uted to antipsychotic medication because, approximately,
half the studies have been conducted in medication-free,
including neuroleptic-naive, patients.
Increased striatal DA, most evident in patients with
active psychotic symptoms, has been related to the
positive symptoms of schizophrenia. More recently,
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neuroreceptor studies have related DA function to
cognitive processes in schizophrenia. Cortical DA trans-
mission via D1 receptors may play a role in impaired
working memory and negative symptoms,76 whereas
striatal DA activity via D2 receptors may modulate
response inhibition, temporal organization, and motor
performance.77
Most neuroreceptor studies have been conducted in
patients with schizophrenia, and it is unclear if the rela-
tion between striatal DA function and psychosis is unique
to schizophrenia or is evident in other disorders with psy-
chotic features. Recent PET studies in bipolar disorder
have examined different systems implicated in the path-
ophysiology of the disorder including serotonin trans-
porter binding78 and the muscarinic receptor.79 Thus,
there is insufficient knowledge to determine whether
receptor neuroimaging can be helpful is differentiating
among psychotic disorders.
Receptor imaging by PET and SPECT allows investi-
gation of in vivo targets for antipsychotic drug action.80
It is now known that extrapyramidal (parkinsonian) side
effects of first-generation antipsychotic drugs result from
high striatal DA D2 receptor blockade (;75%), while
second-generation antipsychotic drugs produce thera-
peutic benefit in relation to modest and transient striatal
D2 receptor occupancy levels (;65%). These neuroimag-
ing observations point to a rationale for the use of rela-
tively low doses of first-generation antipsychotics and
equivalent doses of second generation antipsychotics,81
though use of neuroimaging to determine dose ranges
in a given patient is far from practical. Neuroreceptor
PET/SPECT studies are valuable research tools that
can help examine compounds that may regulate or stabi-
lize DA, as well as nondopaminergic pathways, such as
serotonin, glutamate, and GABA that may offer prom-
ising targets for drug development.
Functional Imaging
Studies of Patients
The functional imaging literature in schizophrenia has
evolved from PET studies measuring glucose metabolism
and blood flow to fMRI studies with activation para-
digms. Diverse neurobehavioral probes have been ap-
plied in activation paradigms, designed to elucidate the
underlying brain circuitry. Tasks applied have evaluated
executive function such as attention, abstraction, and
working memory, as well as declarative and procedural
memory, language, spatial, sensorimotor, and emotion
processing. The breadth of approaches has precluded
the establishment of a functional imaging phenotype of
schizophrenia. Nonetheless, there is an emerging consis-
tency of findings.82
The early emphasis on ‘‘hypofrontality’’ in schizophre-
nia has been refined. A review of the PET literature found
21 resting studies with an overall effect size of 0.64 and 9
activation studies with an overall effect size of 1.13.83 A
more recent review of PET and SPECT studies examined
47 reports with relative resting measures of cerebral
activity, 29 with absolute resting baseline measures,
and 14 activation paradigms. Studies with neurobehavio-
ral probes included similar numbers of those using the
Wisconsin Card Sort Test, the Continuous Performance
Task, and a variety of other probes. While some similar-
ity in the pattern of brain activity was observed across
experiments, there was substantial heterogeneity.84 A po-
tential strength in activation studies is the ability to relate
the extent of activation to performance obtained ‘‘on
line.’’ However, relative underactivation in patients
who have difficulties performing a task may reflect a def-
icit in underlying processes related to that task or lack of
engagement.84,85 Notably, PET and fMRI studies that
attempted to correct for patients’ impairment, by balanc-
ing performance of patients and healthy controls, often
found no hypofrontality or even hyperfrontality.14 In 2
recent systematic reviews, however, 12 N-back (working
memory) fMRI studies and 18 episodic memory studies
with PET or fMRI found ‘‘hypofrontality’’ in dorsolat-
eral and inferolateral prefrontal cortex, respectively.86,87
Glahn et al87 also reported hyperfrontality in medial
areas including (dorsal) anterior cingulate. Antipsychotic
medication is likely to normalize performance on these
tasks and hypofrontality.88 While the majority of studies
were conducted in patients with schizophrenia, reduced
or increased frontal lobe activity is also evident in bipo-
lar disorder,21,22 but direct comparisons of the groups
are rare.89
Regarding the temporal lobe, an early review found
fairly consistent evidence of increased temporal lobe ac-
tivity in 13 SPECT studies and 6 PET studies.90 These
increases were cortical, but Achim and Lepage86 recently
reported bilateral reductions in perfusion in the MTLs.
Perhaps, a hypothesis that will incorporate these findings
will evaluate the interaction between laterality and fron-
tality. For example, lateral cortex hypofrontality and
hypertemporality may interact with a mirror image in
medial hyperfrontality-hypotemporality.
Such a synthesis of the available literature for lateral
cortical regions is certainly in keeping with early and
contemporary accounts of the disconnectivity hypothesis
of schizophrenia and replicated findings of reduced fron-
totemporal and frontoparietal functional connectiv-
ity.91,92 PET, SPECT, and fMRI studies (figure 4) of
disconnectivity are also supported by accounts of reduced
coherence and gamma asynchrony with electroencepha-
lograpy and magnetoencephalography in schizophre-
nia.93,94 Where medial regions have been invoked in
such systems, it has usually been in terms ofmedial frontal
regions modulating lateral frontotemporal interactions.
There is, as yet, no systematic review of this literature
and no generally adopted approach to acquiring and
processing data for functional and effective connectivity
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analyses. Establishing such a framework must be another
priority for the imaging community.
Studies in Relatives and Clinical Utilities
Functional imaging studies in family member of patients
with schizophrenia are limited. There are less than 10
perfusion studies and fewer still reports of disconnectiv-
ity. There are approximately equal numbers of accounts
of hypofrontality, no significant perfusion deficits, and
hyperfrontality under different conditions.95 More
obviously consistent are replicated accounts of PFC
disconnectivity.96–99
Comparative studies of diagnostic specificity are again
few. The possibilities of using functional imaging, and
particularly ligand binding, to predict treatment response
and prognosis have also been understudied, with few rep-
licated results. In a preliminary ‘‘proof of concept’’ study
from the EHRS, fMRI could indeed predict the later de-
velopment of schizophrenia—but this was in a post hoc
analysis of only 4 patients.98
Functional Imaging in Relation to Treatment
Several studies have examined changes in abnormal
brain function in relation to antipsychotic medications.
Davis et al88 reviewed 21 functional imaging (fMRI
and PET) studies involving a pretreatment baseline study
and at least one posttreatment follow-up study. Overall,
the studies suggested normalization of brain function
(ie, patients were more similar to controls following treat-
ment, especially with second-generation antipsychotic
drugs), though a wide variability of findings was evident
due to methodological limitations such as lack of reliabil-
ity of data, varying subject populations, research designs,
and statistical approaches. Functional imaging can also
contribute in pharmacologic provocative studies as well
as in nonpharmacological behavioral interventions.100,101
Conclusions and Recommendations
The field of neuroimaging in psychotic disorders has
made progress especially in schizophrenia, where meth-
ods have been initially applied. While there is increased
consistency within disorders across methods, there is
paucity of work comparing diagnostic specificity of find-
ings. These are exactly the studies required to deconstruct
psychosis.
Steps are underway that begin to provide important
information: there is a growing literature of structural im-
aging studies that prospectively examine patients with
schizophrenia, bipolar disorder, and healthy people;
first-episode patients with psychosis followed longitudi-
nally and family studies of individuals at risk. We have
the tools to move the field ahead and need to apply ex-
perimental designs that will address fundamental ques-
tions. Studies have to include sufficiently large samples
to permit clinical correlations and be longitudinal.
Several steps are essential for progress toward the even-
tual clinical utility of brain imaging in psychiatry. First,
collaborating research groups need to standardize their
approach to data acquisition, processing, and analyses.
This will permit the construction of ‘‘atlases’’ of normal
and abnormal brain development. Such ‘‘4-dimensional’’
(3D brains over time) imaging studies must incorporate
neurobehavioral paradigms necessary for elucidating
brain-behavior relationships most pertinent to these dis-
orders. This approach necessitates multicenter studies in
order to obtain sufficiently large samples. Second, we
need to incorporate pharmacologic probes into fMRI
studies because this may provide valuable information
linking with molecular substrates and with direct thera-
peutic implications. Third, cohort studies need to be set
up around the time of onset of psychosis to establish the
extent to which such abnormalities could be used to de-
fine schizophrenia at an early stage, with a view to early
intervention and possibly even prevention. These studies
could incorporate longitudinal follow-up examinations.
Finally, more data are needed to examine the extent to
which distinct neuroimaging alterations exist across and
within traditional diagnostic boundaries. Such work could
inform on whether the observed abnormalities map onto
clinical features of symptomatoloy, course, and treatment
response dimensions (the phenome) and to specific genetic
polymorphisms (the genome). The availability of such
data will permit an evaluation of the usefulness of neuro-
imaging in the distinction between schizophrenia and af-
fective psychosis and to address a crucial question on how
neural activity changes in association with different levels
and different types of psychosis.
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